Prostate cancer vaccine shows promise in clinical trials

Share this article:
Dendreon's cancer vaccine Provenge has shown promise by extending the lives of patients with prostate cancer, according to a study released this week, the first time a cancer vaccine has been shown to improve survival in any malignancy.
Dendreon, a biotech based in Seattle, Wash., said it will wait for three-year data from an additional 98 patients, which it expects in the second half of this year, before seeking
FDA approval for the vaccine. If the data from that study also show a survival benefit, the company said it will begin discussions with the FDA.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.